A new NBER working paper reveals that doctors practicing alone write more inappropriate opioid prescriptions than doctors working in groups.
Prescription Drugs
Posted inHealth Law
Medical or Recreational? States Debate Where Psychedelics Belong
Amid research on psychedelics to treat mental health conditions, states roll out regulated use.
Posted inCost of Care
Could Health Insurance Bureaucracy Be a Good Thing?
A recent working paper adds fuel to the debate over when and how health insurers should be able to ration people’s use of care.
Posted inCost of Care
Ozempic Hype Forces Employer Calls on Obesity Coverage
Employers are facing a big dilemma: How do they pay for the new highly effective and popular obesity medications without breaking the bank?
Posted inCost of Care
How Patents Help Keep Obesity Drug Prices Sky-High
A recent JAMA study sheds light on how the manufacturers of a class of popular weight-loss drugs have avoided competition from more affordable generics.
Posted inCost of Care
What to Expect When Medicare and Pharma Finally Negotiate Drug Prices
We explain how Medicare’s historic price negotiations with drugmakers will work, and the impact they could have.
Posted inCost of Care
Can Medicare Afford to Foot the Bill for New Alzheimer’s Drugs?
Recent analyses in JAMA and by the Kaiser Family Foundation raise questions about whether Medicare and its beneficiaries can afford a new wave of Alzheimer’s treatments.
Posted inPublic Health
Should Remote Opioid Addiction Treatment Stay in the Mix?
Two recent studies show the impact of an ongoing, COVID-era rule that let doctors treat opioid addiction entirely remotely.
Posted inPublic Health
The Drugs Changing How We Treat Obesity
A new class of drugs can help people lose weight and manage serious health conditions. But they’re also raising difficult questions.
Posted inHealth Law
A Closer Look at the Abortion Medication Mifepristone
What is the abortion drug at the center of a new legal maelstrom–and what happens if patients lose access to it?